How can current EU policy initiatives pave the way towards treatment optimisation as part of health systems?

Webinar on 3 February 2021 from 15:00-17:00 CET

Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>5’</td>
<td>Introduction</td>
<td>Peter O’Donnell</td>
</tr>
<tr>
<td>5’</td>
<td>Opening remarks</td>
<td>MEP Dolors Montserrat – ENVI and BECA Committee</td>
</tr>
</tbody>
</table>
| 40’  | The added value of treatment optimisation | Dr. Denis Lacombe – EORTC Director General  
A case study from the cancer field.  
Prof. Guy Brusselle – Dept. of Respiratory Medicine UZ Gent & ERS  
A case study from the respiratory field |
| 60’  | Roundtable discussion | Panel discussion moderated by Peter O’Donnell with:  
MEP Véronique Trillet-Lenoir – ENVI and EMPL Committee (video message)  
MEP Alessandra Moretti – ENVI and BECA Committee  
Jan Geissler – CML Advocates Network and Patient Advisory Committee member  
Prof. Bengt Jönnson – Professor of Health Economics at SSE  
Dr. Denis Lacombe – EORTC Director General  
Prof. Guy Brusselle – Dept. of Respiratory Medicine UZ Gent & ERS |
|      | Key questions to address: |  
• How can treatment optimisation studies bridge the research gap between the pre-approval development of medicines and their post-approval use in real-life practice?  
• Who should be involved in performing treatment optimisation studies? Is there a role for EMA?  
• How can current and upcoming EU health and research programmes contribute?  
• How can cross-border treatment optimisation studies be taken account of in essentially national decisions on access to health systems?  
• What does ‘patient-centric’ mean in real-life practice? |
| 5’   | Closing remarks | MEP Maria da Graça Carvalho – ITRE Committee |
| 5’   | Take-away messages | Peter O’Donnell |